No Data
H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $62
Promising Clinical Trial Results and Strategic Combination Bolster Buy Rating for Revolution Medicines
Earnings Preview: RVMD to Report Financial Results Post-market on November 06
Unusual Options Activity: QRVO, DECK and Others Attract Market Bets, QRVO V/OI Ratio Reaches 333.3
Barclays Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $60
Guggenheim Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $82